| Ytd | -87.29% | |
| 1y | -99.34% |
| Open | 2.20 | Prev Close | 2.20 | Low | 2.19 | High | 2.33 | Mkt Cap | 3.42M |
| Vol | 176.44K | Avg Vol | 2.24M | EPS | -175.92 | P/E | N/A | Forward P/E | N/A |
| Beta | -1.51 | Short Ratio | 1.88 | Inst. Own | 16.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 4.29 | 200-d Avg | 95.33 | 1yr Est | 0.00 |
CMND News
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
Vancouver, Canada, June 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearm
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearm
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
The patent, which refers to Clearmind's molecule MEAI (5-methoxy-2-aminoindane), covers innovati
Vancouver, Canada, June 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearm
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
Vancouver, Canada, June 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearm
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live Webinar Yale
Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announce
This advancement strengthens Clearmind's robust intellectual property portfolio, which already
Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmi
The approval advances the multicenter study titled "A Phase I/II Single and Multiple Dose Tolera
Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmi
US stocks down, Nasdaq drops 200 points. Dow -0.35% at 49,512.48, Nasdaq -0.93% at 25,849.08, S&
US stocks fall, Dow Jones down 0.34% & NASDAQ down 0.41% in morning trading. Home Depot reports
Vancouver, Canada, May 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmi
Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-st
Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmi
Federal Officials, Researchers, Clinicians and Biopharma Leadership Convene d by Psychedelic Medicin
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
Vancouver, Canada, May 12, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmi
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
The European patent application forms part of the Company's exclusive worldwide licensing agreem
Positive clinical results from Alcohol Use Disorder clinical trial may strengthen potential for elig
Clearmind Medicine Inc. (NYSE: CMND) faces a price correction Wednesday following a massive rally. R
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial
US stocks up as Dow Jones gains 0.48% and NASDAQ rises 0.03%. Retail sales up 1.7% in March, while p
US stocks down at midday, Dow down 0.2%, NASDAQ down 0.52%. Energy up 1.1%, consumer discretionary d
US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric
Clearmind Medicine shares are trading higher Monday after CMND-100 meets the primary endpoint in its
MRVL: 7% | Google Teams Up With Marvell Technology To Build New AI Chips, Invests Heavily In TPU Str
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta
TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $1
